

## ADDICTION SCIENCE & CLINICAL PRACTICE EDITORIAL BOARD

### **Linda Chang, M.D.**

Professor, Department of Medicine  
John A. Burns School of Medicine  
University of Hawaii  
Honolulu, Hawaii

### **Hendree Jones, Ph.D.**

Associate Professor of Behavioral Biology  
Research Director, Center for Addiction and Pregnancy  
Program Director, Cornerstone  
Department of Psychiatry and Behavioral Sciences  
The Johns Hopkins University School of Medicine  
Baltimore, Maryland

### **Thomas R. Kosten, M.D.**

Jay H. Waggoner Chair and Professor of Psychiatry and Neuroscience  
Baylor College of Medicine  
Houston, Texas

### **Patricia Molina, Ph.D.**

Ashman Professor, Department of Physiology  
Louisiana State University Health Sciences Center  
New Orleans, Louisiana

### **Edward V. Nunes, M.D.**

Professor of Clinical Psychiatry  
Columbia University College of Physicians and Surgeons  
New York, New York

### **James Sorenson, Ph.D.**

Professor of Psychiatry  
University of California, San Francisco  
San Francisco General Hospital Medical Center  
San Francisco, California

### **Claire E. Sterk, Ph.D.**

Senior Vice Provost for Academic Planning and Faculty Development  
Charles Howard Candler Professor of Public Health  
Emory University  
Atlanta, Georgia

### **Betty Tai, Ph.D.**

Director, Center for the Clinical Trials Network  
National Institute on Drug Abuse  
Bethesda, Maryland

### **Nancy Waite-O'Brien, Ph.D.**

Consultant  
The Betty Ford Center  
Rancho Mirage, California

## A Note From NIDA's Director

### Progress in Analgesia

The lead article in this issue of *Addiction Science & Clinical Practice* focuses on the blessing and curse of opioids. Drs. Savage, Kirsh, and Passik offer invaluable practical advice, useful to both substance abuse clinicians and pain specialists, on negotiating the difficult clinical issues that arise as a result of opioids' gift of powerful analgesia and their bane of addiction.

While supporting these authors' research to maximize the safe and effective use of opioids, NIDA is also fostering the development of new medications that may relieve severe pain without risk of addiction. Some approaches have already shown promise in laboratory studies with animals. They include inhibiting the neuron-regulating cells called glia and creating new types of compound molecules that simultaneously and selectively interact with multiple receptors. Some of the compounds under study suppress pain many times more powerfully than morphine.

Success in these efforts will markedly advance NIDA's mission to reduce the prevalence and the health and social consequences of drug abuse. Fewer patients will be put at risk of addiction by exposure to opioids during treatment. Hospitals and pharmacies will be able to stock fewer addictive medications, reducing the amount available for diversion. The issues Dr. Savage and her coauthors discuss so authoritatively will not vanish, but many decisions in the treatment of both pain and substance abuse should become simpler.



Nora D. Volkow, M.D.

Director

National Institute on Drug Abuse